Suchergebnisse - Portal für Medizinische Datenmodelle (MDM-Portal)

Suchergebnisse filtern
Datenmodelle auswählen

Ausgewählte Datenmodelle

Sie müssen eingeloggt sein, um mehrere Datenmodelle auszuwählen und diese herunterzuladen oder zu analysieren.

455 Suchergebnisse.

Baseline Local Laboratory Data, Tarceva in NSCLC patients who have EGFR-positive tumors DRKS00001485 NCT00373425 - Baseline Local Laboratory Data, Tarceva in NSCLC patients who have EGFR-positive tumors NCT00373425

- 01.04.22 - 1 Formular, 3 Itemgruppen, 18 Datenelemente, 1 Sprache

Itemgruppen: Hematology, Biochemistry, Pregnancy Tests

Sponsor: OSI Pharmaceuticals Information provided by : Astellas Pharma Inc (OSI Pharmaceuticals) A multicenter, randomized, double-blind, placebo-controlled, phase 3 study of single-agent Tarceva® (erlotinib) following complete tumor resection with or without adjuvant chemotherapy in patients with stage IB-IIIA non-small cell lung carcinoma who have EGFR-positive tumors. See https://clinicaltrials.gov/ct2/show/NCT00373425 Part of study: Baseline Local Laboratory Data

Eligibility Carcinoma, Non-Small-Cell Lung NCT00001499

- 17.11.21 - 1 Formular, 1 Itemgruppe, 20 Datenelemente, 1 Sprache

Itemgruppe: Criteria

Phase II Neoadjuvant Trial of a Continuous Infusion of Paclitaxel Plus Cisplatin Followed by Chest Radiotherapy for Patients With Stage III Non-Small Cell Lung Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00001499

Eligibility Non-Squamous Non-Small Cell Lung Cancer NCT02409342

- 27.09.21 - 1 Formular, 2 Itemgruppen, 16 Datenelemente, 1 Sprache

Itemgruppen: Inclusion Criteria, Exclusion Criteria

A Comparative Study of MPDL3280A (Anti-PDL1 Antibody) With Cisplatin or Carboplatin + Pemetrexed in Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower 110]; ODM derived from: https://clinicaltrials.gov/show/NCT02409342

Eligibility Non-Small Cell Lung Cancer NCT02515435

- 27.09.21 - 1 Formular, 2 Itemgruppen, 22 Datenelemente, 1 Sprache

Itemgruppen: Inclusion Criteria, Exclusion Criteria

The Efficacy and Safety of Apatinib in Heavily Pretreated Advanced Non-squamous Non-small Cell Lung Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT02515435

Eligibility Non-Small Cell Lung Cancer NCT00886678

- 20.09.21 - 1 Formular, 2 Itemgruppen, 11 Datenelemente, 1 Sprache

Itemgruppen: Inclusion Criteria, Exclusion Criteria

A Study of Pemetrexed Plus Carboplatin Combined With Radiation in Patients With Inoperable Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC) (RT0801); ODM derived from: https://clinicaltrials.gov/show/NCT00886678

Eligibility Non-Small-Cell Lung Cancer NCT00705549

- 20.09.21 - 1 Formular, 2 Itemgruppen, 20 Datenelemente, 1 Sprache

Itemgruppen: Inclusion Criteria, Exclusion Criteria

Individualized Therapy Based of Tumoral mRNA Levels of ERCC1, RRM1 and BRCA1 in Advanced Non-Small-Cell Lung Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00705549

Eligibility Non-Small-Cell Lung Cancer NCT00550173

- 20.09.21 - 1 Formular, 2 Itemgruppen, 10 Datenelemente, 1 Sprache

Itemgruppen: Inclusion Criteria, Exclusion Criteria

A Study for Non-Smoker Patients With Nonsquamous Non-Small Cell Lung Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00550173

Eligibility Non-small Cell Lung Cancer NCT00994097

- 20.09.21 - 1 Formular, 2 Itemgruppen, 27 Datenelemente, 1 Sprache

Itemgruppen: Inclusion Criteria, Exclusion Criteria

NGR-hTNF in Combination With Standard Chemotherapy to Treat Patients With Advanced Non-small Cell Lung Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00994097

Eligibility Carcinoma, Non-small-cell Lung NCT02004184

- 20.09.21 - 1 Formular, 2 Itemgruppen, 22 Datenelemente, 1 Sprache

Itemgruppen: Inclusion Criteria, Exclusion Criteria

Pemetrexed in Advanced Non-Small-Cell Lung Cancer: at Progression vs Maintenance Therapy After Induction Chemotherapy; ODM derived from: https://clinicaltrials.gov/show/NCT02004184

Eligibility Carcinoma, Non-Small-Cell Lung NCT01497041

- 20.09.21 - 1 Formular, 2 Itemgruppen, 17 Datenelemente, 1 Sprache

Itemgruppen: Inclusion Criteria, Exclusion Criteria

A Phase II Clinical Trial of Docetaxel, Oxaliplatin Combination Chemotherapy in Patients With Stage IIIB/IV Non-adenocarcinoma, Non-small Cell Lung Cancer (NSCLC) as Second-line Treatment; ODM derived from: https://clinicaltrials.gov/show/NCT01497041

Eligibility Non Small Cell Lung Cancer NCT01017874

- 20.09.21 - 1 Formular, 2 Itemgruppen, 10 Datenelemente, 1 Sprache

Itemgruppen: Inclusion Criteria, Exclusion Criteria

A Study of Alimta/Cisplatin/Gefitinib for Asian Non-smoking Participants With Non Small Cell Lung Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01017874

Eligibility Non Small Cell Lung Cancer NCT01020786

- 20.09.21 - 1 Formular, 2 Itemgruppen, 16 Datenelemente, 1 Sprache

Itemgruppen: Inclusion Criteria, Exclusion Criteria

A Study in Non-squamous Non Small Cell Lung Cancer in Asian Patients; ODM derived from: https://clinicaltrials.gov/show/NCT01020786

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.